幽门螺杆菌阳性消化性溃疡患者的药物治疗方案成本——效果分析

Cost-effectiveness Analysis of several pharmacotheraphy Protocols for helicobacter pylori-positive peptic ulcers

目的评价3种治疗幽门螺杆菌阳性消化性溃疡患者的药物治疗方案的成本—效果。方法选择120例幽门螺杆菌阳性消化性溃疡患者,随机分为3组:A方案为奥美拉唑+克拉霉素+甲硝唑,B方案为奥美拉唑+阿莫西林+替硝唑,C方案为奥美拉唑+左氧氟沙星+呋喃唑酮,应用药物经济学的成本—效果分析方法进行评价。结果A、B、C方案成本分别为98.37元、102.76元、137.48元;总有效率分别为85.37%、94.74%、95.12%;成本—效果比分别为1.15、1.08、1.45;B、C组相对于A组的增量成本—效果比分别为0.47、4.01。结论通过药物经济学的分析,B方案为较佳的治疗方案。

To evaluate the cost-effectiveness of 3 therapeutic regimes in the treatment of patients with Heli-cobacterPylori. Methods 120 cases of patients with HelicobacterPylori were divided into three groups random-ly： Group A is Omeprazole, Clarithromycin and metronidazole; Group B is OmePrazole, Amoxicillin and Tinida-zole; Group C is Omeprazole, levofloxacin and Furazolidone. The data were evaluated with cost-effectiveness analysis. Results The costs for group A. B and C were 98.37 yuan, 102.76 yuan and 137.48 yuan, respec-tively; The effective rates were 85.37%, 94.74% and 95.12%, ,respectively; The cost-effectiveness ratio were 1.15. 1.08 and 1.45, respectively; The incremental cost-effectiveness ratios of group B and C vs group A were 0.47 and 4.01, respectively. ConclusJons Regime B was superior than the other therapeutic regimes.